Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cancer Genetics Inc (CGIX)

Cancer Genetics Inc (CGIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,833
  • Shares Outstanding, K 4,085
  • Annual Sales, $ 7,310 K
  • Annual Income, $ -6,710 K
  • 60-Month Beta 2.72
  • Price/Sales 1.59
  • Price/Cash Flow 41.72
  • Price/Book 2.40
Trade CGIX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.10
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 11/18/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.30 +7.21%
on 03/30/21
7.48 -38.37%
on 03/22/21
-1.90 (-29.19%)
since 02/26/21
3-Month
2.61 +76.63%
on 12/29/20
17.50 -73.66%
on 02/10/21
+1.90 (+70.11%)
since 12/28/20
52-Week
2.11 +118.73%
on 10/30/20
17.50 -73.66%
on 02/10/21
+1.53 (+49.68%)
since 03/27/20

Most Recent Stories

More News
Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Roland J. Carrillo, PhD as Vice President of Business Development

RUTHERFORD, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today the appointment...

CGIX : 4.61 (-2.33%)
Cancer Genetics to Present at the Annual 33rd ROTH Conference

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...

CGIX : 4.61 (-2.33%)
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts,...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm

INVESTIGATION ALERT: Halper Sadeh LLP Investigates PRGX, RP, NK, CGIX; Shareholders Are Encouraged to Contact the Firm NEW YORK, NY / ACCESSWIRE / February 4, 2021 / Halper Sadeh LLP, a global investor...

RP : 88.72 (+0.08%)
PRGX : 7.71 (+0.13%)
NK : 32.49 (+14.89%)
CGIX : 4.61 (-2.33%)
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced...

CGIX : 4.61 (-2.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company's tests target cancers, including hematological, urogenital, and HPV-associated...

See More

Key Turning Points

3rd Resistance Point 5.16
2nd Resistance Point 4.92
1st Resistance Point 4.77
Last Price 4.61
1st Support Level 4.38
2nd Support Level 4.14
3rd Support Level 3.99

See More

52-Week High 17.50
Fibonacci 61.8% 11.62
Fibonacci 50% 9.80
Fibonacci 38.2% 7.99
Last Price 4.61
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar